Download Our Paper
Download our white paper on how to overcome the biggest obstacles in conducting an acute myeloid leukemia clinical trial
Click on the image to the left to begin your download
In light of the impact Acute Myeloid Leukemia has on individuals and society as a whole, continued research and awareness efforts are crucial to improve diagnosis, treatment, and ultimately, patients' quality of life.
The development of clinical trial protocols that meet FDA approval standards is crucial for the success of new AML treatments.
If you have any questions, please feel free to contact us directly.
Acute Myeloid Leukemia Clinical Trials
Acute Myeloid Leukemia (AML) is a life-threatening form of leukemia characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.
The understanding of AML has evolved significantly over the last few decades. Recent years have seen a shift towards more targeted therapies, driven by deeper molecular and genetic insights.
iNGENū's team of experienced researchers and clinicians specializes in designing and conducting innovative studies. Leveraging enhanced trial design and comprehensive patient-centric strategies, we are committed to accelerating the development of new treatments for Acute Myeloid Leukemia.
Roughly
20k
new cases of AML are diagnosed annually in the United States
The median age of diagnosis for AML is
68
years old
The 5-year survival rate for AML is around
28%
varying based on age and other factors
Our clinical team has over
120
years of combined clinical trial experience
Understand the iNGENū CRO difference
Request a Proposal
- Book a Discovery Call with one of our Advisors by completing the form below
- We will put forward a proposal and strategy within 5 business days